Leah L. Blitz Dmd, Pllc | |
3136 Route U.s. 11 Lisle NY 13797 | |
(607) 692-4987 | |
(607) 692-4996 |
Full Name | Leah L. Blitz Dmd, Pllc |
---|---|
Speciality | Dentist - General Practice |
Location | 3136 Route U.s. 11, Lisle, New York |
Authorized Official Name and Position | Leah L Blitz (OWNER-DENTIST) |
Authorized Official Contact | 6076924987 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Leah L. Blitz Dmd, Pllc 3136 Route U.s. 11 Lisle NY 13797 Ph: (607) 692-4987 | Leah L. Blitz Dmd, Pllc 3136 Route U.s. 11 Lisle NY 13797 Ph: (607) 692-4987 |
NPI Number | 1710762885 |
---|---|
Provider Enumeration Date | 08/28/2023 |
Last Update Date | 08/28/2023 |
Identifier | Type | State | Issuer |
---|---|---|---|
1710762885 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
A landmark study led by Prof. Michael P. Vallely, MBBS, PhD, FRACS, of Sydney Heart and Lung Surgeons and the University of Sydney will be published in the February 28, 2017 issue of the Journal of the American College of Cardiology.
A team from the University of Pennsylvania, Children's Hospital of Philadelphia, and University of Wisconsin-Madison are launching a project to develop new strategies for treating vision disorders using cells implanted in the retina.
Tests of antibiotic resistance in cattle have revealed stark variation across thirteen European countries. The results, published in BioMed Central's open-access journal Acta Veterinaria Scandinavica, show that major differences were apparent in the occurrence of resistance between countries and between the different antimicrobial agents tested.
Politics were at work as Deborah Taylor, the chief financial officer of the Centers for Medicare and Medicaid Services, faced tough questioning during a House Energy and Commerce Subcommittee On Oversight and Investigations hearing regarding the financial controls applied to this aspect of Medicare — a generally complex and obscure part of the program.
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.
› Verified 4 days ago